Search Results for: search.php

New multifunctional materials can save resources, costs, and energy while providing innovative applications. In addition to the use of environment-friendly…

The bunyavirus family includes five different groups of viruses which trigger serious illnesses in humans and animals and which can also cause significant…

Male moths locate females by navigating along the latter's pheromone (odor) plume, often flying hundreds of meters to do so. Two strategies are involved to…

According to the invention the approach of an easy risk assessment of patients with diagnosed cardiac insufficiency is based on the measurement of concentration of a pro-tein in whole blood called MD-2 by using the ELISA-technology. ELISA (Enzyme-Linked-Immunosorbent-Assay) is a common and standardized immunological assay for the detection of specific molecules in body liq-uids. It is well known that for cardiac degen-eration the activation of toll-like receptor-4 (TLR 4) is important. TLR 4 and MD-2 then form a receptor complex.
By the additional use of MD-2 biomarker to the “gold-standard” biomarker BNP for risk stratification of cardiac insufficiency, an in-crease of sensitivity and specificity regarding to the long-term survival can be realized. The used biomarker for this assay, is a MD-2 protein (also called LY96) which relates to the group of so-called “Immune response receptors”.

Scientists from Goethe University of Frankfurt am Main have identified serum biomarkers that differentiate patients with hepatocellular carcinoma (HCC) from those with liver cirrhosis. The identified sphingolipid metabolites C16-ceramide and sphingosine-1-phosphate (S1P) provide an extraordinary high diagnostic accuracy (AUC value > 0.98). Current HCC tests measure levels of alpha-fetoprotein (AFP) which show a significantly lower diagnostic performance.

At a traditional stone-laying ceremony outside La Serena, Chile on April 14th, construction officially began of the Large Synoptic Survey Telescope (LSST)….